Iterum Therapeutics (NASDAQ:ITRM) posted its quarterly earnings results on Wednesday. The company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.50) by ($0.43), Fidelity Earnings reports. Iterum Therapeutics had a negative return on equity of 83.95% and a negative net margin of 11,956.64%.
ITRM stock traded up $0.06 during midday trading on Friday, hitting $6.76. The company’s stock had a trading volume of 1,440 shares, compared to its average volume of 8,010. The company has a market cap of $106.79 million, a PE ratio of -0.95 and a beta of 2.05. Iterum Therapeutics has a 12 month low of $4.70 and a 12 month high of $11.22. The company has a current ratio of 4.36, a quick ratio of 4.36 and a debt-to-equity ratio of 0.24. The firm’s 50-day moving average is $6.64 and its 200-day moving average is $6.84.
Several research firms recently weighed in on ITRM. Royal Bank of Canada cut their price target on Iterum Therapeutics to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 15th. HC Wainwright restated a “buy” rating and issued a $17.00 price target on shares of Iterum Therapeutics in a research note on Thursday. Finally, Zacks Investment Research raised Iterum Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 17th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $15.75.
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Read More: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.